“MV140 is a sublingual bacterial #vaccine developed in Spain by Inmunotek, and has been approved for use there since 2010.

Since its development, it has been used for patients in several European countries through special access programs, including in the U.K., Sweden, Australia and New Zealand, among others.
Now, it is heading to Canada.
Red Leaf Medical, which owns the licence for #Uromune (MV140) in Canada, filed a new drug submission with #HealthCanada a year ago.”

https://www.ctvnews.ca/health/sublingual-vaccine-for-urinary-tract-infections-is-awaiting-approval-by-health-canada-1.6303000